Tentarix said its platform creates next generation antibody-based multifunctional biotherapeutics that achieve unprecedented specificity and unique activity.
Such products can conditionally activate or inhibit specific cell populations, for example, only activating immune cells that kill cancer cells without activating other immune cells that may create adverse effects.
Previously, the field of multifunctional biotherapeutics has been largely limited to engaging only two targets and has predominantly focused on a few areas of biology, such as T cell engagers.
These limitations are due to challenges in discovering molecules that have the desired pharmacology, functional activity, and manufacturability.
Tentarix said it overcomes these historical challenges. The company's proprietary platform facilitates high throughput discovery and optimization of biotherapeutics with high cell selectivity, differentiated functionality, and robust mammalian expression that enables molecular developability.
The company has generated proof of concept data in multiple receptor classes.
The lead program is a multifunctional therapeutic with one subunit that targets the IL2R gamma receptor, a subunit that targets the IL2R beta receptor and other subunits that bind to cell surface proteins on a specific subset of T cells.
Potent activity only occurs when all targets are engaged simultaneously to direct powerful biology to this important subset of cells.
Tentarix is advancing programs in many other fields including cell type specific reprogramming and cell population specific delivery and internalization.
Tentarix is led by an executive team with experience in discovering and developing biologics.
More than 30 individuals that include experts in protein engineering, cell surface proteomics, and discovery technology have been assembled in San Diego, California and Vancouver, British Columbia.
Versant Ventures is a healthcare venture capital firm. Samsara BioCapital is a biotech investment fund.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886